With specialised bio safety containment facilities in Hyderabad, Malur, Ankleshwar, and Pune, Bharat Biotech steadily moves towards its aim of ~ 1 billion doses of annualised capacity.
Product manufactured from Ankleshwar facilities will be available for supplies starting September 2021
Bharat Biotech, a global leader in
India has done better than any country in the world as regards to affordability and the reach to the people of COVID-19 vaccines, Bharat Biotech Chairman and Managing Director Krishna Ella said on Sunday.
Highlighting the enormity of the task of vaccination, Ella said, “When you
Health Minister Mansukh Mandaviya declared through a tweet that India has given approval to Johnson & Johnson's single-dose COVID-19 vaccine for emergency use. Meanwhile the company said it was too early to predict by when delivery is possible.
Earlier on the large medical conglomerate had applied
Prequalification will fast-track procurement and global access of ROTAVAC 5D®
The only rotavirus vaccine in the world to be delivered in a 0.5 ml dose volume
Bharat Biotech today announced that the World Health Organization (WHO) has awarded prequalification to its rotavirus vaccine, ROTAVAC 5D®.
Dr. Krishna Ella, CMD, Bharat Biotech appreciated the efforts of Doctors’ and support staff during an event to commemorate World Hepatitis Day at KIMS Hospitals
Dr. Krishna Ella, Chairman & Managing Director, Bharat Biotech today said that Science and Innovation in India is on par with
India’s Covaxin, developed by Bharat Biotech in collaboration with the Indian Council of Medical Research, effectively neutralises both Alpha and Delta variants of coronavirus, the US’ National Institute of Health has said. The NIH said results of two studies of blood serum from people who
Bharat Biotech hereby communicates the following message regarding pricing of COVAXIN® for Central Government, State Governments, and Private Hospitals, we believe it is pertinent to place facts on record for the Media and the public at large, so that they can understand and appreciate our
The recruitment for the clinical trial of the country’s first indigenously-developed COVID-19 vaccine, Covaxin, among children in the age group of 6-12 years will begin at the AIIMS here from Tuesday.
This will be followed by the clinical trial of children in the age-group of 2-6